INSM - Insmed - Stock Price & Dividends

Insmed Incorporated is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for patients with rare and serious diseases worldwide.

The company's flagship product, ARIKAYCE, is a treatment for Mycobacterium avium complex lung disease, which is a chronic and debilitating condition that affects the lungs. ARIKAYCE is used as part of a combination antibacterial drug regimen for adult patients, providing a much-needed solution for those affected by this rare disease.

In addition to ARIKAYCE, Insmed is also developing a promising pipeline of products, including Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1. This medication has the potential to treat patients with bronchiectasis, a chronic respiratory condition characterized by recurring lung infections, as well as other neutrophil-mediated diseases.

Another key product in Insmed's pipeline is Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug. This treatment is being developed to address pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension, both of which are life-threatening conditions that affect the lungs and heart.

With a rich history dating back to 1988, Insmed is headquartered in Bridgewater, New Jersey, and has established itself as a leader in the biopharmaceutical industry. The company's commitment to innovation and patient-centric approach has enabled it to make a meaningful impact on the lives of patients and their families.

For more information about Insmed and its innovative therapies, please visit their website at https://www.insmed.com.